Muscle mass loss during GLP1 receptor agonist therapy prevented with GDF8 and activin A blockade Kokura, Yoji, et al., Science Direct (2024)
The disease burden, while showing a global decline in age-standardized incidence rates between 1990 and 2019, remains significant and continues to exhibit substantial geographic and demographic disparities, particularly in individuals aged 4064, the group with the highest incidence
M., Liu, H
Top-Down Approach The top-down approach used macro-level indicators: Parent market benchmarks Global/regional industry trends Economic indicators (GDP, demographics, spending patterns) Penetration and usage ratios This approach was used for segments where granular data were limited or inconsistent
However, some patients benefit from switching to alternative GLP-1 compounds or dosing protocols that produce gentler weight loss trajectories
Hashimotos Disease